Prenetics Global (NASDAQ:PRE – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.
Institutional & Insider Ownership
25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Prenetics Global and 10x Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prenetics Global | -191.73% | -16.45% | -13.34% |
| 10x Genomics | -28.93% | -25.07% | -19.41% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prenetics Global | 0 | 0 | 1 | 0 | 3.00 |
| 10x Genomics | 1 | 7 | 8 | 1 | 2.53 |
Prenetics Global currently has a consensus target price of $9.00, suggesting a potential upside of 65.75%. 10x Genomics has a consensus target price of $25.14, suggesting a potential upside of 61.38%. Given Prenetics Global’s stronger consensus rating and higher possible upside, equities analysts clearly believe Prenetics Global is more favorable than 10x Genomics.
Valuation and Earnings
This table compares Prenetics Global and 10x Genomics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prenetics Global | $25.56 million | 1.94 | -$62.72 million | ($3.99) | -1.36 |
| 10x Genomics | $629.74 million | 2.99 | -$255.10 million | ($1.53) | -10.18 |
Prenetics Global has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Prenetics Global has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.
Summary
10x Genomics beats Prenetics Global on 9 of the 15 factors compared between the two stocks.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
